MX347981B - Composicion de anticuerpos pan-her. - Google Patents

Composicion de anticuerpos pan-her.

Info

Publication number
MX347981B
MX347981B MX2013004899A MX2013004899A MX347981B MX 347981 B MX347981 B MX 347981B MX 2013004899 A MX2013004899 A MX 2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A MX 347981 B MX347981 B MX 347981B
Authority
MX
Mexico
Prior art keywords
family
pan
antibody compositions
antibody composition
directed
Prior art date
Application number
MX2013004899A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004899A (es
Inventor
Lantto Johan
Wandahl Pedersen Mikkel
Kragh Michael
Jacobsen Helle
K Christensen Ida
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2013004899A publication Critical patent/MX2013004899A/es
Publication of MX347981B publication Critical patent/MX347981B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2013004899A 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her. MX347981B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
PCT/IB2011/054834 WO2012059857A2 (en) 2010-11-01 2011-10-31 Pan-her antibody composition

Publications (2)

Publication Number Publication Date
MX2013004899A MX2013004899A (es) 2013-07-15
MX347981B true MX347981B (es) 2017-05-22

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Country Status (13)

Country Link
US (1) US9217039B2 (OSRAM)
EP (3) EP2635604B1 (OSRAM)
JP (2) JP6033783B2 (OSRAM)
KR (2) KR101773120B1 (OSRAM)
AU (2) AU2011324871B2 (OSRAM)
CA (2) CA2816520C (OSRAM)
DK (1) DK2635604T3 (OSRAM)
ES (2) ES2692379T3 (OSRAM)
IL (2) IL225954B (OSRAM)
MX (2) MX347981B (OSRAM)
PL (1) PL2635604T3 (OSRAM)
TW (1) TW201231066A (OSRAM)
WO (2) WO2012059858A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331577B1 (en) * 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
DK2516469T3 (en) 2009-12-22 2016-05-02 Roche Glycart Ag ANTI-HER3 antibodies and uses thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
CN103429262A (zh) * 2011-03-15 2013-12-04 梅里麦克制药股份有限公司 克服对erbb途径抑制剂的抗性
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
HUE033279T2 (en) * 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
JP2015514710A (ja) * 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
WO2013164689A2 (en) * 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US10081681B2 (en) * 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2959775A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN110621698B (zh) 2017-04-05 2024-04-12 法国施维雅药厂 靶向pd-1、tim-3及lag-3的组合疗法
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
BR112021004287A2 (pt) * 2018-09-07 2021-08-03 Pfizer Inc. anticorpos anti-avss8 e composições e usos dos mesmos
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CA3130248A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3.
JP7774293B2 (ja) * 2019-07-24 2025-11-21 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4271709A1 (en) 2020-12-31 2023-11-08 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024240634A1 (en) 2023-05-19 2024-11-28 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PT896586E (pt) 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
RU2426795C2 (ru) 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
AU2005287404B2 (en) 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
AU2005314127A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
HRP20131113T1 (hr) * 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
PL2132229T3 (pl) * 2007-03-01 2016-12-30 Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka
NZ581316A (en) 2007-05-25 2012-02-24 Symphogen As Method for manufacturing a recombinant polyclonal protein
CA2702322A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
BRPI0910454A2 (pt) 2008-04-23 2018-03-27 Symphogen As processo para produção de uma proteína policlonal
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
EP2331577B1 (en) * 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
AU2009301505A1 (en) 2008-10-06 2010-04-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
CN102356092B (zh) * 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
DK2417156T3 (en) * 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
AU2010233994A1 (en) * 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
EP2467164A2 (en) 2009-08-21 2012-06-27 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
EP2486052A4 (en) 2009-10-09 2013-05-01 Merck Sharp & Dohme GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES
NO2719708T3 (OSRAM) 2009-11-13 2018-03-24
TW201141519A (en) 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
WO2011136911A2 (en) * 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
ES2692379T3 (es) 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones

Also Published As

Publication number Publication date
CA2816520A1 (en) 2012-05-10
EP3156421B1 (en) 2018-06-06
MX348637B (es) 2017-06-22
KR101773120B1 (ko) 2017-08-30
EP2635605A1 (en) 2013-09-11
MX2013004899A (es) 2013-07-15
KR20140026337A (ko) 2014-03-05
WO2012059858A1 (en) 2012-05-10
EP2635605A4 (en) 2014-10-22
AU2011324870A1 (en) 2013-01-31
CA2816520C (en) 2017-11-21
JP6033783B2 (ja) 2016-11-30
ES2692379T3 (es) 2018-12-03
TW201231066A (en) 2012-08-01
PL2635604T3 (pl) 2017-09-29
WO2012059857A3 (en) 2012-07-19
CA2816519C (en) 2019-01-15
JP2014503189A (ja) 2014-02-13
KR101862832B1 (ko) 2018-05-30
AU2011324871A1 (en) 2013-05-09
IL225954B (en) 2018-05-31
MX2013004897A (es) 2013-07-15
AU2011324871B2 (en) 2016-05-19
EP2635605B1 (en) 2018-07-25
WO2012059857A2 (en) 2012-05-10
EP3156421A1 (en) 2017-04-19
IL225954A0 (en) 2013-07-31
JP6186277B2 (ja) 2017-08-23
KR20140026336A (ko) 2014-03-05
CA2816519A1 (en) 2012-05-10
ES2616961T3 (es) 2017-06-14
JP2014503188A (ja) 2014-02-13
DK2635604T3 (en) 2017-02-27
EP2635604B1 (en) 2016-11-30
AU2011324870B2 (en) 2015-01-29
US9217039B2 (en) 2015-12-22
US20130287684A1 (en) 2013-10-31
EP2635604A2 (en) 2013-09-11
IL225953A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
MX2013004899A (es) Composicion de anticuerpos pan-her.
PH12012501993A1 (en) Pyrazolyl quinazoline kinase ihibitors
NZ604003A (en) Monoclonal antibodies against her2
IN2012DN02081A (OSRAM)
NZ626610A (en) Antibodies that bind csf1r
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
TN2012000462A1 (en) Anti-cd40 antibodies
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
CU20140036A7 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
PH12013500648A1 (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
NZ602992A (en) Prophylaxis of colorectal and gastrointestinal cancer
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
PH12012502102A1 (en) Fused bicyclic kinase inhibitors
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
NZ757754A (en) Antibodies that bind csf1r
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
UA108500C2 (ru) Неконкурентные антагонисты никотиновых рецепторов

Legal Events

Date Code Title Description
FG Grant or registration